Paper Details

  1. Home
  2. Paper Details

Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.

Author: ChakrabartiShaon, Frisco-CabanosHeidie, HataAaron, MakhninAlex, McDonaldThomas O, MichorFranziska, NapoliChelsi, PoelsKamrine E, SchoenfeldAdam J, ShiManli, TanWeiwei, TobiYosef, WangYuli, WeinrichScott L, YuHelena A

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study used computational modeling and experimental data to identify an optimal dosing schedule for the combination therapy of osimertinib and dacomitinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC). The proposed schedule was subsequently validated in a clinical trial.
Paper Details　
Original Abstract of the Article :
Despite the clinical success of the third-generation EGFR inhibitor osimertinib as a first-line treatment of EGFR-mutant non-small cell lung cancer (NSCLC), resistance arises due to the acquisition of EGFR second-site mutations and other mechanisms, which necessitates alternative therapies. Dacomiti...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211846/

データ提供：米国国立医学図書館（NLM）

Optimizing Dosing Schedules for EGFR-Mutant Non-Small Cell Lung Cancer

EGFR-mutant non-small cell lung cancer (NSCLC) is a particularly aggressive form of lung cancer. It's like a wildfire in the desert, spreading rapidly and fiercely. This study explored the potential of combining two targeted therapies, dacomitinib and osimertinib, to improve treatment outcomes and potentially delay the emergence of resistance. The researchers aimed to find the optimal dosage schedule for this combination therapy, like carefully selecting the right blend of sand and water to create a resilient oasis.

A Collaborative Approach to Cancer Treatment

The authors employed an integrated computational modeling and experimental approach to identify the optimal dosing schedule for dacomitinib and osimertinib. This innovative approach leverages the power of data analysis and experimental validation to refine treatment strategies. It's like using a map and a compass to navigate the complex terrain of cancer treatment, ensuring a more efficient and effective journey.

Precision Medicine: Tailoring Treatment to the Individual

This research exemplifies the principles of precision medicine, tailoring treatment plans based on individual patient characteristics and tumor biology. By understanding the unique features of each case, healthcare providers can optimize treatment strategies and maximize the chances of a successful outcome. It's like customizing a camel caravan to suit the specific challenges of the desert terrain, ensuring a safe and successful journey.

Dr.Camel's Conclusion

This study highlights the promise of personalized medicine in treating EGFR-mutant NSCLC. The use of computational modeling and experimental validation allows for a more precise and effective approach to dosing, potentially leading to improved outcomes for patients. Just as a skilled caravan leader adapts to the changing desert landscape, so too must we embrace a personalized approach to cancer treatment, ensuring that each patient receives the most effective care possible.

Date :
  1. Date Completed 2021-07-07
  2. Date Revised 2022-09-28
Further Info :

Pubmed ID

34140482

DOI: Digital Object Identifier

PMC8211846

Related Literature

Article Analysis
・Effects of dacomitinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.